Natixis Advisors 13F Portfolio

The biggest add is telling: NVIDIA was lifted another 12.5% in shares, boosting a $4.31B position that already sits at 4.85% of the book and is up 260.9% versus Natixis’s average cost. They are not “harvesting” this gain; they are underwriting another leg higher in the AI data center capex cycle.

Behind that headline, they are quietly loading the ecosystem. KLA was ramped by 54.3% to $874.0M, while Applied Materials, Lam Research, ASML and Micron all saw double‑digit or high‑single‑digit share increases. The message: the bottlenecks that matter are yield, lithography, memory and process control, not just GPU supply.

On the platform side, Apple, Microsoft, Alphabet (both share classes) and Amazon all saw 8–12% share increases, signaling confidence that hyperscale cloud and handset refresh demand will monetize AI at the application layer. Outside of tech, Eli Lilly, UnitedHealth, AstraZeneca and other health names were increased aggressively, suggesting Natixis wants durable, pricing‑power cash flows to sit opposite the high‑beta AI stack.

Finally, broad beta is used surgically: Vanguard’s S&P 500 proxy VOO was boosted by 25.0% and the mid‑cap VO and small‑cap IJR were each raised by double digits, giving them cheap, liquid exposure they can dial up or down as the single-name book evolves.

The primary funding leg is not a sector; it’s structure. Natixis cut SPDR’s SPYM by 29.1% and Vanguard’s VUG by 16.7%, shedding nearly $250.4M combined in estimated value to pay for higher-conviction individual equities and a bigger VOO position. This is a classic “from wrappers into hand‑picked growth” move.

Within tech, they nudged down Analog Devices by 9.3% despite a triple‑digit gain versus cost, likely a relative-value call within semis in favor of more levered AI beneficiaries. GE Aerospace was trimmed 4.6% after a powerful rerating, while Boeing saw a smaller 2.1% cut, hinting at some skepticism on near‑term aerospace execution despite the longer‑term aero upcycle.

On the defensive side, Merck and Exxon Mobil were both modestly reduced, down 3.8% and 3.6% in shares, respectively. These aren’t repudiations; they look like measured harvests from mature, cash‑rich franchises to fund higher growth in pharma peers like AstraZeneca and in AI‑linked capex. In short, the book’s cash is being re‑routed from broad, lower‑beta exposures into narrower, higher‑conviction pillars.

Despite the aggressive single‑name activity, sector weights barely budged at the headline level: technology went from 56.1% to 55.9% of the disclosed book. Under the surface, though, there’s a trade‑up from generalized growth ETFs into specific AI and chip‑tool names, raising the portfolio’s idiosyncratic tech risk without changing the sector label.

Health care is the only sector with a clear net build, moving from 7.3% to 7.8% through sizable adds to Eli Lilly, UnitedHealth, Johnson & Johnson, AstraZeneca, Novartis and AbbVie. That’s a diversified bet on innovation plus insured demand, pairing obesity and oncology optionality with predictable managed‑care earnings.

Energy slipped from 1.5% to 1.3% as Exxon Mobil was shaved, and consumer staples edged down with only a token increase in Coca‑Cola. Real estate “by label” (Visa and Mastercard) actually reflects a rising bet on global payments rails, while finance and industrials weights were roughly flat as the firm nudged banks and industrials like Caterpillar up and aerospace down. The unclassified ETF bucket ticked lower, reinforcing the shift from broad beta toward stock selection.

Put together, this quarter’s moves say Natixis wants to own the full AI stack — GPUs, memory, lithography, and the hyperscalers deploying them — and is willing to accept more single‑name volatility in exchange for that upside. The adds to NVIDIA, KLA, Lam Research, Applied Materials, ASML, AMD and Micron form a coherent bet that AI infrastructure remains underbuilt and will command outsized capital for years.

At the same time, the build‑out in health care and the steady hand in banks, payments and consumer stalwarts like Walmart and Coca‑Cola give the portfolio shock absorbers if the AI trade stutters. These are not heroic macro timing calls; they are classic quality‑and‑cash‑flow anchors.

The willingness to fund all this by trimming broad growth ETFs and legacy defensives, rather than by cutting the AI complex itself, shows where conviction truly lies. Unless the data change dramatically, expect future quarters to look similar: incremental pruning of low‑information exposure, and incremental concentration in the handful of platforms and chip‑tool vendors Natixis believes will own the AI capex curve.